SCHEMBL22845208

SCHEMBL22845208

CNC(=O)c1ccc(-n2c(=O)c3c(n4ncc(NCc5ccc(OCC(N)=O)cc5)c24)CN(C(=O)c2ccc(Cl)c(Cl)c2)CC3)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRLHR P49683 4/20 0.35
MAPT P10636 6/20 0.32
POLB P06746 1/20 0.32
TP53 P04637 3/20 0.32
PLA2G1B P04054 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ATG4B Q9Y4P1 1/20 0.32
SCD O00767 1/20 0.32
SLC6A4 P31645 4/20 0.32
HRH3 Q9Y5N1 4/20 0.32
SLC6A2 P23975 2/20 0.31
SLC6A3 Q01959 2/20 0.31
GRIN2C Q14957 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22845525 0.94 PRLHR (0.34) PRLHRMAPTPOLBTP53HDAC6
SCHEMBL22845294 0.90 PRLHR (0.37) PRLHRMAPTPOLBCYP2C9
SCHEMBL22845518 0.90 PRLHR (0.35) PRLHRMAPTPOLBSLC6A4HRH3
SCHEMBL22845379 0.89 PREP (0.36) PRLHRMAPTPOLBSMN1; SMN2HDAC6
SCHEMBL22845418 0.89 PRLHR (0.34) PRLHR
SCHEMBL22845325 0.85 MAPT (0.41) PRLHRMAPTPOLBTP53SMN1; SMN2
SCHEMBL24173968 0.84 PRLHR (0.36) PRLHRMAPTPOLBCYP2C9
SCHEMBL22845234 0.84 PRLHR (0.34) PRLHRMAPTPOLBTP53HDAC6
SCHEMBL22845341 0.84 PREP (0.37) MAPTPOLBSMN1; SMN2MEN1ALDH1A1
SCHEMBL22845388 0.83 PREP (0.35) PRLHRSMN1; SMN2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL PRLHR 2579/4885MAPT 651/4885POLB 3198/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL PRLHR 2579/4885MAPT 651/4885POLB 3198/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL PRLHR 2579/4885MAPT 651/4885POLB 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.